A biotechnology company in the USA has been granted authorization to conduct clinical trials with the Cuban drug Heberprot-P, which is used for the treatment of diabetic foot ulcers. Discovery Therapeutics Caribe, a specialized biotechnology company, has received permission from the FDA to carry out phase three clinical trials with Heberprot-P.
Heberprot-P, an intralesional recombinant human epidermal growth factor, is used to treat complex ulcers, a common complication of diabetes. The drug is manufactured at the Center for Genetic Engineering and Biotechnology in Cuba and has been successfully used in over 400,000 diabetic foot ulcer patients worldwide since its initial approval in Cuba in 2006.
While Heberprot-P is currently marketed in twenty countries, the USA is not included in the list. The drug is considered one of BioCubaFarma’s star products with high scientific recognition. This collaboration between a US company and a Cuban state biotechnology company highlights the potential for international partnerships in the field of biotechnology and healthcare.